Oral salmon calcitonin--pharmacology in osteoporosis (Q37798836)

23 August 2017

Oral salmon calcitonin--pharmacology in osteoporosis (English)

1 reference

23 August 2017

0 references

1 reference

2

Anne-Christine Bay-Jensen

1 reference

23 August 2017

4

Morten Asser Karsdal

1 reference

23 August 2017

Kim Henriksen

1

1 reference

PubMed ID

20932224

23 August 2017

Claus Christiansen

series ordinal

3

1 reference

PubMed ID

20932224

23 August 2017

language of work or name

English

0 references

publication date

11 October 2010

1 reference

Expert Opinion on Biological Therapy

23 August 2017

1 reference

23 August 2017

10

1 reference

23 August 2017

11

1 reference

23 August 2017

1617-1629

1 reference

Bone quality--the material and structural basis of bone strength and fragility

23 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526104

Are nonresorbing osteoclasts sources of bone anabolic activity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526104

Local communication on and within bone controls bone remodeling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526104

Oral salmon calcitonin induced suppression of urinary collagen type II degradation in postmenopausal women: a new potential treatment of osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526104

The effect of oral calcitonin on cartilage turnover and surface erosion in an ovariectomized rat model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526104

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526104

Colonic drug delivery: an updated review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526104

Oral delivery of salmon calcitonin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526104

Transmucosal delivery systems for calcitonin: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526104

Bioavailability and biological efficacy of a new oral formulation of salmon calcitonin in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526104

Optimized chemical structure of nanoparticles as carriers for oral delivery of salmon calcitonin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526104

In vivo evaluation of an oral salmon calcitonin-delivery system based on a thiolated chitosan carrier matrix

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526104

Reversible lipidization for the oral delivery of salmon calcitonin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526104

Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526104

Thiomers for oral delivery of hydrophilic macromolecular drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526104

pH-sensitive microsphere delivery increases oral bioavailability of calcitonin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526104

Calcitonin for osteoporosis and bone pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526104

Oral delivery of insulin with the eligen technology: mechanistic studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526104

Approaches to oral drug delivery for challenging molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526104

Carrier-enhanced human growth hormone absorption across isolated rabbit intestinal tissue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526104

Influence of food intake on the bioavailability and efficacy of oral calcitonin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526104

Optimizing bioavailability of oral administration of small peptides through pharmacokinetic and pharmacodynamic parameters: the effect of water and timing of meal intake on oral delivery of Salmon Calcitonin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526104

Investigation of the diurnal variation in bone resorption for optimal drug delivery and efficacy in osteoporosis with oral calcitonin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526104

Calcitonin-induced change in serum calcium levels and its relationship to osteoclast morphology and number of calcitonin receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526104

Effects of salmon calcitonin on trabecular microarchitecture as determined by magnetic resonance imaging: results from the QUEST study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526104

Calcitonin: a drug of the past or for the future? Physiologic inhibition of bone resorption while sustaining osteoclast numbers improves bone quality

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526104

Assessment of osteoclast number and function: application in the development of new and improved treatment modalities for bone diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526104

Optimising antiresorptive therapies in postmenopausal women: why do we need to give due consideration to the degree of suppression?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526104

New mechanisms and targets in the treatment of bone fragility

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526104

Application of a new serum assay for type I collagen cross-linked N-telopeptides: assessment of diurnal changes in bone turnover with and without alendronate treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526104

Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526104

Denosumab for prevention of fractures in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526104

Discontinuous calcitonin treatment of established osteoporosis--effects of withdrawal of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526104

Osteoclast-derived activity in the coupling of bone formation to resorption.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526104

Bisphosphonate treatment suppresses not only stochastic remodeling but also the targeted repair of microdamage

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526104

Targeted and nontargeted remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526104

The role of collagen in bone strength

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526104

The effects of oral calcitonin on bone collagen maturation: implications for bone turnover and quality.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526104

Is bone quality associated with collagen age?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526104

Over-suppression of bone turnover: does it exist?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526104

Teriparatide reduces bone microdamage accumulation in postmenopausal women previously treated with alendronate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526104

Disease-specific risk for an osteonecrosis of the jaw under bisphosphonate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526104

Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526104

Evolving data about subtrochanteric fractures and bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526104

Calcitonin for treating acute pain of osteoporotic vertebral compression fractures: a systematic review of randomized, controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526104

Analgesic efficacy of calcitonin for vertebral fracture pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526104

Epidural calcitonin: does it provide better postoperative analgesia? An analysis of the haemodynamic, endocrine, and nociceptive responses of salmon calcitonin and opioids in epidural anesthesia for hip arthroplasty surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526104

The effect of calcitonin on beta-endorphin levels in postmenopausal osteoporotic patients with back pain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526104

Calcitonin and relief of pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526104

Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526104

Analgesic effect of calcitonin in osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526104

Analgesic effect of salmon calcitonin suppositories in patients with acute pain due to recent osteoporotic vertebral crush fractures: a prospective double-blind, randomized, placebo-controlled clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526104

Calcitonin in phantom limb pain: a double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526104

Calcitonin in reflex sympathetic dystrophy syndrome and other painful conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526104

The effect of adding calcitonin to physical treatment on reflex sympathetic dystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526104

The frozen shoulder: diagnosis and treatment. Prospective study of 50 cases of adhesive capsulitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526104

Intranasal calcitonin for the prevention of bone erosion and bone loss in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526104

Antinociceptive activity of salmon calcitonin: electrophysiological correlates in a rat chronic pain model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526104

Migraine prophylaxis with salmon calcitonin: a cross-over double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526104

Effects of amylin and salmon calcitonin on beta-endorphin-induced growth hormone and prolactin secretion in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526104

Use of calcitonin in the treatment of bone pain associated with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526104

Should subchondral bone turnover be targeted when treating osteoarthritis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526104

Targeting subchondral bone for treating osteoarthritis: what is the evidence?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526104

The role of subchondral bone remodeling in osteoarthritis: reduction of cartilage degeneration and prevention of osteophyte formation by alendronate in the rat anterior cruciate ligament transection model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526104

Application of biochemical markers in development of drugs for treatment of osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526104

The effect of oral salmon calcitonin delivered with 5-CNAC on bone and cartilage degradation in osteoarthritic patients: a 14-day randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526104

Investigation of the direct effects of salmon calcitonin on human osteoarthritic chondrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526104

Molecular pharmacology of the calcitonin receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526104

Diabetogenic effects of salmon calcitonin are attributable to amylin-like activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526104

Pramlintide in the treatment of diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526104

New drugs for type 2 diabetes mellitus: what is their place in therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526104

Effect of acute and chronic administration of calcitonin on serum glucose in patients with Paget's disease of bone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526104

Calcitonin, a diabetogenic hormone?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526104

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526104

10.1517/14712598.2010.526104

21 January 2018

Identifiers

DOI

1 reference

23 August 2017

1 reference

PubMed ID

20932224